Development of New Genome Editing Tools for the Treatment of Hyperlipidemia

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Oct 27

PMID 37887310

Authors

Giulio Preta

Affiliations

Soon will be listed here.

Abstract

Hyperlipidemia is a medical condition characterized by high levels of lipids in the blood. It is often associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Traditional treatment approaches for hyperlipidemia involve lifestyle modifications, dietary changes, and the use of medications like statins. Recent advancements in genome editing technologies, including CRISPR-Cas9, have opened up new possibilities for the treatment of this condition. This review provides a general overview of the main target genes involved in lipid metabolism and highlights the progress made during recent years towards the development of new treatments for dyslipidemia.

Citing Articles

Isosteric 3D Bicyclo[1.1.1]Pentane (BCP) Core-Based Lipids for mRNA Delivery and CRISPR/Cas Gene Editing.

Wu S, Yang Y, Lian X, Zhang F, Hu C, Tsien J J Am Chem Soc. 2024; 146(50):34733-34742.

PMID: 39655603 PMC: 11717372. DOI: 10.1021/jacs.4c13154.

Landscape of Gene Variants in Phenotypic Manifestations of Autism Spectrum Disorder: A Systematic Review.

Cooper J, Mittal J, Sangadi A, Klassen D, King A, Zalta M J Clin Med. 2024; 13(7).

PMID: 38610832 PMC: 11012327. DOI: 10.3390/jcm13072067.

References

Su X, Peng D . New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases. Lipids Health Dis. 2018; 17(1):12. PMC: 5769531. DOI: 10.1186/s12944-018-0659-y. View

Ganji S, Kamanna V, Kashyap M . Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003; 14(6):298-305. DOI: 10.1016/s0955-2863(02)00284-x. View

Waseem Ghani M, Iqbal A, Ghani H, Bibi S, Wang Z, Pei R . Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation. J Mater Chem B. 2023; 11(24):5251-5271. DOI: 10.1039/d2tb02610d. View

Young S, Northey S, McCarthy B . Low plasma cholesterol levels caused by a short deletion in the apolipoprotein B gene. Science. 1988; 241(4865):591-3. DOI: 10.1126/science.3399894. View

Schirris T, Renkema G, Ritschel T, Voermans N, Bilos A, van Engelen B . Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015; 22(3):399-407. DOI: 10.1016/j.cmet.2015.08.002. View

Fan J, Kitajima S, Watanabe T, Xu J, Zhang J, Liu E . Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. Pharmacol Ther. 2014; 146:104-19. PMC: 4304984. DOI: 10.1016/j.pharmthera.2014.09.009. View

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

10.

Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3):203-12. DOI: 10.1056/NEJMoa1300955. View

11.

Lim G . Dyslipidaemia: Balancing the benefits and risks of statin therapy. Nat Rev Cardiol. 2016; 13(11):632-633. DOI: 10.1038/nrcardio.2016.164. View

12.

Tardif J, Karwatowska-Prokopczuk E, Amour E, Ballantyne C, Shapiro M, Moriarty P . Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022; 43(14):1401-1412. PMC: 8986458. DOI: 10.1093/eurheartj/ehab820. View

13.

Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P . Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2010; 11(1):11-27. PMC: 3267165. DOI: 10.2174/156652311794520111. View

14.

Li B, Luo X, Deng B, Wang J, McComb D, Shi Y . An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015; 15(12):8099-107. PMC: 4869688. DOI: 10.1021/acs.nanolett.5b03528. View

15.

McDonagh M, Peterson K, Holzhammer B, Fazio S . A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016; 22(6):641-653q. PMC: 10397903. DOI: 10.18553/jmcp.2016.22.6.641. View

16.

Stankov S, Cuchel M . Gene editing for dyslipidemias: New tools to "cut" lipids. Atherosclerosis. 2023; 368:14-24. PMC: 10493168. DOI: 10.1016/j.atherosclerosis.2023.01.010. View

17.

Sacks F, Alaupovic P, Moye L, Cole T, Sussex B, Stampfer M . VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000; 102(16):1886-92. DOI: 10.1161/01.cir.102.16.1886. View

18.

Nissen S, Lincoff A, Brennan D, Ray K, Mason D, Kastelein J . Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15):1353-1364. DOI: 10.1056/NEJMoa2215024. View

19.

Wang L, Breton C, Warzecha C, Bell P, Yan H, He Z . Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol Ther. 2021; 29(6):2019-2029. PMC: 8178442. DOI: 10.1016/j.ymthe.2021.02.020. View

20.

Leren T, Berge K . Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia. Clin Chim Acta. 2008; 397(1-2):92-5. DOI: 10.1016/j.cca.2008.07.025. View